AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller Humira in a ...
The label update provides an option for patients who have received at least 1 approved systemic therapy if TNF blockers are clinically inadvisable.
(Reuters) -AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller ...
This lens points to three standouts in retail, healthcare, and consumer goods. One pairs a modest yield with rapid hikes ...
The FDA has approved an updated indication for upadacitinib (Rinvoq; AbbVie) in inflammatory bowel disease (IBD), allowing its use in adults with moderately to severely active ulcerative colitis or ...
ABIVAX Société Anonyme's Obefazimod shows robust efficacy and differentiation in early Phase 3 trials. Click here to read why ...
Updated indication allows the use of RINVOQ® (upadacitinib) prior to the use of tumor necrosis factor (TNF) blocking agents in patients for whom ...
With significant hedge fund interest and trending on Reddit, AbbVie Inc. (NYSE:ABBV) secures a spot on our list of the 10 ...
As in any month, September was eventful for AbbVie. In addition to news about its usual activities, it also scored big with ...
The global rheumatoid arthritis drugs market was valued at US$31.27 billion in 2024 and is projected to reach US$56.62 billion by 2033, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback